Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Lee, Ann Sing
Zee, Benny C. Y.
Cheung, Foon Yiu
Kwong, Philip
Cheng, Ashley Chi Kin
Lai, Maria
Kwok, Chloe
Chong, Marc
Jolivet, Jacques
Chiang, C. L.
Leung, K. C.
Siu, Steven
Lee, Conrad
Tung, Stewart Yuk
机构：
[1] Tuen Mun Hosp, Tuen Mun, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[3] Queen Elizabeth Hosp, Kowloon, Hong Kong, Peoples R China
[4] Queen Mary Hosp, North Point, Hong Kong, Peoples R China
[5] Princess Margaret Hosp, Hong Kong, Hong Kong, Peoples R China
[6] Aegera Therapeut Pharmasci Inc, Montreal, PQ, Canada
[7] Princess Margaret Hosp, Kowloon, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4105
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Perspective phase II study of combination sorafenib plus Mitomycin-C in the treatment of advanced hepatocellular carcinoma (HCC)
    Dima, G.
    Lucia, M.
    La Gattuta, G.
    Toscano, R.
    Filippelli, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 49 - 49
  • [32] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Ma, Yuk Ting
    Peck-Radosavljevic, Markus
    Ross, Paul J.
    Graham, Janet Shirley
    Fartoux, Laetitia
    Deptala, Andrzej
    Wenz, Arne
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Meyer, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [33] A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC)
    Duffy, Austin G.
    Ma, Chi
    Ulahannan, Susanna Varkey
    Makarova-Rusher, Oxana V.
    Fioravanti, Suzanne
    Walker, Melissa
    Venkatesan, Aradhana
    Turkbey, Ismail B.
    Choyke, Peter L.
    Trepel, Jane B.
    Cao, Liang
    Compton, Kathryn
    Figg, William Douglas
    Greten, Tim F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [34] Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom M.
    Trojan, Jorg
    Cebon, Jonathan S.
    Liem, Andre K. D.
    Lipton, Lara Rachel
    Gupta, Charu
    Wu, Benjamin
    Litten, Jason B.
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [35] Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Iyer, Renuka
    Sonti, Sahithi
    Mahalingam, Devalingam
    Mukherjee, Sarbajit
    Chakraborty, Sayan
    Attwood, Kristopher
    George, Anthony
    Maguire, Orla
    Minderman, Hans
    Fountzilas, Christos
    CANCER RESEARCH, 2024, 84 (07)
  • [36] Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    O'Neil, Bert H.
    Bendell, Johanna C.
    Modiano, Manuel R.
    Machiels, Jean-Pascal H.
    Versola, Melissa Jo
    Hodge, Jeff Paul
    Sawarna, Karen
    Tse, Nielson
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [37] A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC)
    Harding, James J.
    Abou-Alfa, Ghassan K.
    Shi, Yuankai
    Whang-Peng, Jacqueline
    Yuen, Man Fung
    Saif, Wasif M.
    Tian, Aiping
    Gu, Shanzhi
    Lam, Wing
    Liu, Shwu-Huey
    Cheng, Yung-Chi
    Chu, Edward
    Yen, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [38] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
    Abou-Alfa, Ghassan K.
    Niedzwieski, Donna
    Knox, Jennifer J.
    Kaubisch, Andreas
    Posey, James
    Tan, Benjamin R.
    Kavan, Petr
    Goel, Rakesh
    Murray, John J.
    Bekaii-Saab, Tanios S.
    Tam, Vincent Channing
    Rajdev, Lakshmi
    Kelley, Robin Kate
    Siegel, Abby
    Balletti, Jennifer
    Harding, James J.
    Schwartz, Lawrence Howard
    Goldberg, Richard M.
    Bertagnolli, Monica M.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [39] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)
    Abou-Alfa, Ghassan K.
    Niedzwieski, Donna
    Knox, Jennifer J.
    Kaubisch, Andreas
    Posey, James
    Tan, Benjamin R.
    Kavan, Petr
    Goel, Rakesh
    Lammers, Philip Edward
    Bekaii-Saab, Tanios S.
    Tam, Vincent Channing
    Rajdev, Lakshmi
    Kelley, Robin Kate
    Siegel, Abby B.
    Balletti, Jennifer
    Harding, James J.
    Howard, Lawrence Schwartz
    Goldberg, Richard M.
    Bertagnolli, Monica M.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma ( HCC) and chronic viral hepatitis.
    Sun, W.
    Nelson, D.
    Alberts, S. R.
    Poordad, F.
    Leong, S.
    Teitelbaum, U. R.
    Woods, L.
    Fox, N.
    O'Neil, B. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345